Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Cyclooxygenase-2 Inhibitors as Radiosensitizers in Cancer Therapy
FY 2011-12
Summary
Solid tumors are among the leading causes of death in Western countries, with a steadily increasing number of cancer patients every year. Although the prognosis for these patients has improved over the last decade, there is still an urgent need for novel and more efficient treatment modalities. New targets for anticancer treatment are required, and new drugs that target specific parts of tumor resistance to therapies and drugs are being developed at an increasing rate. Among these new drugs are inhibitors of cyclooxygenase (COX), the key enzyme within the inflammatory pathway which involves the conversion of arachidonic acid into prostaglandins (PGs), represent a particularly promising class of compounds for chemoprevention and cancer therapy. Specifically, the inducible isoform of the COX enzyme, COX-2, is known to be associated with the formation of carcinogens, regulation of angiogenesis, migration and invasion of cells, and the
inhibition of apoptosis, all of which contribute to cancer progression. The major downstream product of COX-2, prostaglandin E2 (PGE2), has been found to protect cancer cells from apoptosis, amongst other cancer-promoting functions.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
254427
Name
Marshall Alison
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Cyclooxygenase-2 Inhibitors as Radiosensitizers in Cancer Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apoptosis; Cancer Therapy; Cyclooxygenase; Cycloxygenase-2 Inhibitors; Prostaglandin E2; Radiosensitization; Radiotherapy; Tumors
Abstract
Solid tumors are among the leading causes of death in Western countries, with a steadily increasing number of cancer patients every year. Although the prognosis for these patients has improved over the last decade, there is still an urgent need for novel and more efficient treatment modalities. New targets for anticancer treatment are required, and new drugs that target specific parts of tumor resistance to therapies and drugs are being developed at an increasing rate. Among these new drugs are inhibitors of cyclooxygenase (COX), the key enzyme within the inflammatory pathway which involves the conversion of arachidonic acid into prostaglandins (PGs), represent a particularly promising class of compounds for chemoprevention and cancer therapy. Specifically, the inducible isoform of the COX enzyme, COX-2, is known to be associated with the formation of carcinogens, regulation of angiogenesis, migration and invasion of cells, and the
inhibition of apoptosis, all of which contribute to cancer progression. The major downstream product of COX-2, prostaglandin E2 (PGE2), has been found to protect cancer cells from apoptosis, amongst other cancer-promoting functions.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Marshall, Alison
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~